基因突变特征可预测非小细胞肺癌免疫治疗获益
研究基于350例NSCLC患者数据筛选52个候选基因,发现其中至少2个基因突变的复合突变特征与ICB治疗显著获益相关,中位OS为36个月对8个月;该特征预测能力优于TMB-H,并在156例独立队列中验证,中位PFS为8.3个月对3.5个月。
要点
- 52基因中≥2个突变的复合特征与ICB治疗显著OS获益相关。
- 该特征预测ICB获益优于TMB-H,低TMB患者亦可从该特征识别获益。
- 独立队列中该特征与更长PFS相关,支持其作为预测生物标志物。
核心结论
- 52个候选基因中至少2个基因突变的遗传特征在预测NSCLC患者ICB治疗临床获益方面优于TMB-H。
研究设计与样本
- 利用已发表的350例NSCLC患者队列数据筛选候选基因并评估突变特征对ICB疗效的影响,并与TMB-H比较。
- 在156例接受ICB治疗的NSCLC患者独立队列中评估不同突变特征的预测能力。
主要发现
- 52个候选基因中≥2个基因突变的复合突变特征见于350例NSCLC患者中的145例,与 considerable ICB治疗获益相关。
- 在350例NSCLC患者中,52基因中≥2个突变者与无突变者的中位总生存期分别为36个月对8个月。
- 具有复合突变特征但TMB低(<10)的患者,与无该特征但TMB-H(≥10)的患者相比,获得显著总生存获益。
- 在156例接受ICB治疗的NSCLC独立队列中,具有复合突变特征者与无突变者的中位无进展生存期分别为8.3个月对3.5个月。
临床怎么用
- 对于NSCLC患者,可考虑检测52个候选基因的突变状态以识别可能从ICB治疗中获益的人群,尤其TMB低者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Identification of patients who can benefit from immune checkpoint blockade (ICB) therapy is key for improved clinical outcome. Recently, U.S. Food and Drug Administration approved tumor mutational burden (TMB) high (TMB-H or TMB ≥ 10) as a biomarker for pembrolizumab treatment of solid tumors. We intend to test the hypothesis that mutations in select genes may be a better predictor of NSCLC response to ICB therapy than TMB-H. METHODS: We compiled a list of candidate genes that may predict for benefits from ICB treatment by use of data from a recently published cohort of 350 patients with NSCLC. We then evaluated the influences of different mutation signatures in the candidate genes on ICB efficacy. They were also compared with TMB-H. The predictive powers of different mutation signatures were then evaluated in an independent cohort of patients with NSCLC treated with ICB. RESULTS: A compound mutation signature, in which two or more of the 52 candidate genes were mutated, accounted for 145 of 350 patients with NSCLC and was associated with considerable ICB treatment benefits. Specifically, the median duration of overall survival was 36 versus 8 months in NSCLC in those with two or more versus none of the 52 genes mutated. Moreover, those patients with the compound mutation signature but had low TMB (<10) achieved significant overall survival benefits when compared with those without the signature but had TMB-H (≥10). Finally, in an independent cohort of 156 patients with ICB-treated NSCLC, the median duration of progression-free survival was 8.3 months versus 3.5 months in those with the compound mutation signature versus those with none mutated in the 52 genes. CONCLUSIONS: A genetic signature with mutations in at least two of 52 candidate genes was superior than TMB-H in predicting clinical benefits for ICB therapy in patients with NSCLC.
引用
- Pan D, Hu AY, Antonia SJ, et al. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. J Thorac Oncol. 2020. PMID: 33307194. doi:10.1016/j.jtho.2020.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。